Company Overview - Proris is a data-driven clinical research service provider focused on patient-centered approaches, creating a comprehensive project management system for clinical trials [1] - The company has established a nationwide network of clinical trial institutions, serving over 960 clinical trial institutions and covering more than 1,300 sites [2] - As of June 2025, Proris has undertaken over 4,200 international and domestic clinical projects, with 2,538 active projects [3] Industry Trends - In 2025, the number of drug clinical trials registered in China reached 5,173, a year-on-year increase of 6.44% [2] - The National Medical Products Administration approved 76 Class 1 innovative drugs, marking a 58% increase and a historical high [2] - China accounts for approximately 30% of the global pipeline of new drugs, ranking second worldwide [2] Financial Performance - Since its listing, Proris has distributed a total of CNY 46.1455 million in cash dividends to shareholders, emphasizing its commitment to shareholder returns [2] Competitive Advantages - The company has strong competitive advantages in various therapeutic areas, including hematologic tumors, thoracic tumors, digestive tumors, and rare diseases [3] - Proris is positioned as a key link between the research and clinical ends of the pharmaceutical innovation ecosystem, enhancing the efficiency and quality of new drug development in China [3] Quality Management - Proris has undergone 281 inspections by national and provincial authorities, 14 by the FDA, and 5 by the EMA, with no major findings reported [4] - The company has established a systematic quality management framework, including over 280 standard operating procedures (SOPs) to ensure compliance and quality [4] Recruitment and Training - The recruitment plan is based on existing and new project needs, with a focus on optimizing the recruitment structure to adapt to market demands and regulatory standards [5] - Proris emphasizes a robust training system to enhance employee skills and ensure high-quality service delivery [5]

Company Overview - Proris is a data-driven clinical research service provider focused on patient-centered clinical trials, aiming to enhance the efficiency and compliance of clinical trial management for innovative drug development [1][2] - Since its establishment, Proris has undertaken over 4,200 SMO projects, with 2,538 currently active, and has a workforce of 4,271 employees [2] - The company has served over 960 clinical trial institutions across more than 200 cities in China, benefiting over 420,000 participants and assisting in the approval of over 210 new drugs [2] Financial Performance - Proris has distributed a total of CNY 46.1455 million in cash dividends since its listing, reflecting a commitment to shareholder returns [2] Industry Demand - In 2025, the number of drug clinical trials in China reached 5,173, a year-on-year increase of 6.44%, with 76 innovative drugs approved, marking a 58% increase [3] - China holds approximately 30% of the global new drug pipeline, ranking second worldwide, indicating a vibrant landscape for innovative drug development [3] Market Trends - The total value of innovative drug licensing transactions in China exceeded USD 130 billion in 2025, with over 150 transactions, setting a historical record [3] - The SMO industry is experiencing a trend towards consolidation, with leading firms expanding their client resources and operational capabilities, while smaller firms are gradually exiting the market [4] Client Base - Proris primarily serves multinational pharmaceutical companies, domestic innovative drug firms, and CROs, collaborating with all of the top 10 global pharmaceutical companies as of 2024 [5] Digital Transformation - The company emphasizes the development and application of digital and intelligent technologies as a key strategic focus, aiming to enhance project execution efficiency through a collaborative clinical trial management platform [6] Quality Management - Proris has established a comprehensive quality management system, having undergone 281 inspections by national and provincial authorities, as well as 14 FDA and 5 EMA inspections, with no major findings reported [7][9] - The company maintains over 280 standard operating procedures (SOPs) to ensure compliance and quality in its operations [9]